首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2023800篇
  免费   157336篇
  国内免费   5621篇
耳鼻咽喉   27833篇
儿科学   63459篇
妇产科学   56707篇
基础医学   296923篇
口腔科学   57166篇
临床医学   189813篇
内科学   386316篇
皮肤病学   40624篇
神经病学   167749篇
特种医学   76469篇
外国民族医学   531篇
外科学   293857篇
综合类   49244篇
现状与发展   3篇
一般理论   692篇
预防医学   168897篇
眼科学   46253篇
药学   150570篇
  6篇
中国医学   4392篇
肿瘤学   109253篇
  2018年   21847篇
  2017年   16626篇
  2016年   18223篇
  2015年   21073篇
  2014年   29482篇
  2013年   45360篇
  2012年   61933篇
  2011年   65526篇
  2010年   38205篇
  2009年   35383篇
  2008年   60581篇
  2007年   64566篇
  2006年   64577篇
  2005年   62988篇
  2004年   60647篇
  2003年   57940篇
  2002年   56096篇
  2001年   87457篇
  2000年   89624篇
  1999年   75600篇
  1998年   22123篇
  1997年   20177篇
  1996年   19833篇
  1995年   18813篇
  1994年   17814篇
  1993年   16664篇
  1992年   61798篇
  1991年   60508篇
  1990年   59054篇
  1989年   56303篇
  1988年   52568篇
  1987年   51517篇
  1986年   49058篇
  1985年   47136篇
  1984年   35961篇
  1983年   30752篇
  1982年   18913篇
  1981年   17033篇
  1979年   34438篇
  1978年   24685篇
  1977年   20504篇
  1976年   19620篇
  1975年   20571篇
  1974年   25384篇
  1973年   24617篇
  1972年   23116篇
  1971年   21512篇
  1970年   20134篇
  1969年   19007篇
  1968年   17556篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
Objective: Human epidermal growth factor receptor 2 (erbb2/HER2) overexpression, has now been implicatedin advanced gastric and gastroesophageal junction cancers. The study was conducted to determine the rate of HER2positivity in patients with locally advanced or metastatic gastric and gastroesophageal adenocarcinoma in North-EastIndia and to assess the impact of various demographic and clinical parameters on HER2 positivity. Methods: A total of68 patients of age >18 years of gastric and gastroesophageal adenocarcinoma diagnosed on histopathological examinationfrom September 2016 to February 2018 at Dr B Borooah Cancer Institute, Assam were enrolled for the observational(epidemiological) study. All patients were subjected to the HER2 immunohistochemistry test using a FDA-approved,standardized test kit. HER2 expression was correlated with various demographic and clinicopathological parameters.Results: The overall rate of HER2 positivity in the population studied was 56% (n=38). The rate was non-significantlyhigher in male, older age group (>60 years) and Hindu population. Similarly, HER2 positivity rate was higher in patientswith well differentiated histology and was more common in patients with stage II and III diseases, but neither of theassociations is statistically significant. HER2 positivity rate was significantly higher in proximal and in GEJ tumours(56% versus 44%, P=0.002). Conclusion: HER2 overexpression was evident in 56% of the North-East Indian patientswith locally advanced and metastatic gastric and gastroesophageal adenocarcinoma. The overexpression correlatedsignificantly with primary tumour site. Routine testing of gastric and gastroesophageal tumours for HER2 expressionis recommended to provide a therapeutic advantage in Indian patients.  相似文献   
52.
53.
54.

Objective

Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.

Methods

Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.

Results

In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.

Conclusions

Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection.  相似文献   
55.
56.
57.
58.
59.
60.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号